MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

New research highlights a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD), formerly ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Medically reviewed by Robert Burakoff, MD Fatty liver disease is a health condition in which fat builds up in the liver. This ...

Often symptomless, fatty liver disease is becoming a leading cause of liver cancer. Learn the role of daily habits, early ...

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

South Korea: A large population-based study from South Korea has revealed a significant association between cholecystectomy ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague symptoms like constant fatigue or nausea.

A new analysis from the Chile BiLS study evaluated the reliability of ultrasound imaging for diagnosing SLD in a high-risk ...

China: A large-scale U.S. analysis has revealed that people living with both type 2 diabetes (T2DM) and chronic kidney ...

Source Reference: Ochoa-Allemant P, et al "Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.1809.

Steatotic liver disease (SLD) was highly prevalent among adults with cardiometabolic risk factors, prolonged alcohol intake, or both combined and affected 70% of participants overall.